Skip to main content

Rabbit Recombinant Monoclonal Complement Factor I antibody. Suitable for IP, WB and reacts with Human samples. Cited in 1 publication.

Be the first to review this product! Submit a review

Images

Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (AB278524), expandable thumbnail
  • Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (AB278524), expandable thumbnail
  • Immunoprecipitation - Anti-Factor I/CFI antibody [EPR23948-48] (AB278524), expandable thumbnail

Publications

Key facts

Isotype
IgG
Host species
Rabbit
Storage buffer

Preservative: 0.01% Sodium azide
Constituents: 59.94% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Form
Liquid
Clonality
Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
ICC/IFIPWBIHC-PFlow Cyt (Intra)
Human
Not recommended
Tested
Tested
Not recommended
Not recommended
Mouse
Not recommended
Not recommended
Not recommended
Not recommended
Not recommended
Rat
Not recommended
Not recommended
Not recommended
Not recommended
Not recommended

Not recommended
Not recommended

Species
Human, Mouse, Rat
Dilution info
-
Notes

-

Tested
Tested

Species
Human
Dilution info
1/30
Notes

-

Not recommended
Not recommended

Species
Mouse, Rat
Dilution info
-
Notes

-

Tested
Tested

Species
Human
Dilution info
1/1000
Notes

-

Not recommended
Not recommended

Species
Mouse, Rat
Dilution info
-
Notes

-

Not recommended
Not recommended

Species
Human, Mouse, Rat
Dilution info
-
Notes

-

Not recommended
Not recommended

Species
Human, Mouse, Rat
Dilution info
-
Notes

-

Target data

Function

Trypsin-like serine protease that plays an essential role in regulating the immune response by controlling all complement pathways. Inhibits these pathways by cleaving three peptide bonds in the alpha-chain of C3b and two bonds in the alpha-chain of C4b thereby inactivating these proteins (PubMed:17320177, PubMed:7360115). Essential cofactors for these reactions include factor H and C4BP in the fluid phase and membrane cofactor protein/CD46 and CR1 on cell surfaces (PubMed:12055245, PubMed:2141838, PubMed:9605165). The presence of these cofactors on healthy cells allows degradation of deposited C3b by CFI in order to prevent undesired complement activation, while in apoptotic cells or microbes, the absence of such cofactors leads to C3b-mediated complement activation and subsequent opsonization (PubMed:28671664).

Alternative names

IF, CFI, Complement factor I, C3B/C4B inactivator

Recommended products

Rabbit Recombinant Monoclonal Complement Factor I antibody. Suitable for IP, WB and reacts with Human samples. Cited in 1 publication.

Key facts

Isotype
IgG
Form
Liquid
Clonality
Monoclonal
Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number
EPR23948-48
Purification technique
Affinity purification Protein A
Concentration
Loading...

Storage

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Notes

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Factor I also known as Complement Factor I (CFI) is a serine protease involved in the complement system. Its molecular mass is approximately 88 kDa consisting of a heavy and a light chain linked by a disulfide bond. This protein is mainly expressed in the liver and circulates in the plasma. Factor I inhibits the complement pathways by cleaving complement components C3b and C4b preventing the formation of C3 and C5 convertases.

Biological function summary

Factor I plays a role in maintaining immune homeostasis by preventing excessive complement activation. It acts within a complex that includes cofactors such as Factor H Complement Factor 4 binding protein (C4BP) and Membrane Cofactor Protein (MCP). These interactions allow Factor I to selectively degrade activated complement components ensuring that complement activity is kept in check to avoid host cell damage.

Pathways

Factor I operates in both the classical and alternative complement pathways. In the classical pathway it regulates C3b and C4b breakdown to control the formation of the C3 convertase. In the alternative pathway Factor I works in conjunction with Factor H to degrade C3b. This regulation is important to prevent runaway activation protecting healthy tissue from complement-mediated damage.

Associated diseases and disorders

Factor I deficiencies can lead to conditions like atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD). In aHUS insufficient Factor I activity permits unregulated complement activation leading to thrombotic microangiopathy. In AMD aberrant complement activation contributes to retinal damage and degeneration. These conditions illustrate the need for balanced Factor I activity to prevent disease.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

3 product images

  • Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (ab278524), expandable thumbnail

    Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (ab278524)

    Blocking and diluting buffer and concentration: 5% NFDM/TBST

    The molecular weight observed is consistent with what has been described in the literature (PMID: 17597211).

    Low expression: A549 (PMID:17548110).

    Exposure time: Lanes 1-3: 15 seconds; Lanes 4-6: 5.5 seconds.

    All lanes: Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (ab278524) at 1/1000 dilution

    Lane 1: HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg

    Lane 2: A549 (human lung carcinoma epithelial cell) whole cell lysate at 20 µg

    Lane 3: Human liver tissue lysate at 40 µg

    Lane 4: Human lung tissue lysate at 40 µg

    Lane 5: Human small intestine tissue lysate at 40 µg

    Lane 6: Human plasma at 10 µL

    Secondary

    All lanes: Western blot - VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) at 1/1000 dilution

    Predicted band size: 66 kDa

    Observed band size: 50-88 kDa

  • Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (ab278524), expandable thumbnail

    Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (ab278524)

    Blocking and diluting buffer and concentration: 5% NFDM/TBST

    Factor I/CFI is a glycoprotein, and de-glycosylation resulted in a decrease of MW (lanes 2 and 4). Different band sizes of CFI heavy chain in liver and HepG2 lysates (lanes 1 and 3) observed may be caused by different glycosylation levels.

    Exposure time: 26 seconds.

    All lanes: Western blot - Anti-Factor I/CFI antibody [EPR23948-48] (ab278524) at 1/1000 dilution

    Lane 1: Human liver tissue lysate at 20 µg

    Lane 2: Human liver tissue lysate treated with PNGase F at 20 µg

    Lane 3: HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg

    Lane 4: HepG2 whole cell lysate treated with PNGase F at 20 µg

    Secondary

    All lanes: Western blot - VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) at 1/2000 dilution

    Predicted band size: 66 kDa

    Observed band size: 40 kDa, 50 kDa, 75 kDa, 88 kDa

  • Immunoprecipitation - Anti-Factor I/CFI antibody [EPR23948-48] (ab278524), expandable thumbnail

    Immunoprecipitation - Anti-Factor I/CFI antibody [EPR23948-48] (ab278524)

    Factor I/CFI was immunoprecipitated from 0.35 mg HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate 10 ug with ab278524 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab278524 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.

    Lane 1: HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate 10 ug

    Lane 2: ab278524 IP in HepG2 whole cell lysate

    Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of abid in HepG2 whole cell lysate

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 76 seconds

    All lanes: Immunoprecipitation - Anti-Factor I/CFI antibody [EPR23948-48] (ab278524)

    Predicted band size: 66 kDa

    Observed band size: 50-88 kDa

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com